Diagonal Bio’s CEO Karin Wehlin increases ownership

Diagonal Bio AB’s (”Diagonal Bio” or the ”Company”) CEO, Karin Wehlin, has directly and through Wehlin’s fully owned company WW Advise AB purchased 8,500,000 shares in the Company to a total price of approximately SEK 170,000 (average price SEK 0.02 per share). The acquisition has been made in the market during 11-12 February 2025.

"I had a top underwriting commitment in the recently conducted rights issue and since we had such a successful outcome with an oversubscription of the issue, I was not allocated any units besides my pro-rata part. Based on this and of course based on my strong belief in the team at Diagonal Bio and the future of the Company, I decided to purchase shares in the market to increase my holdings." - Karin Wehlin, CEO of Diagonal Bio AB (publ)

For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO

Phone: +46 703 052488

E-mail: [email protected]

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

E-mail: [email protected]

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.